Adaptive Biotechnologies Q3 Earnings Call Highlights
Published . Updated .
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
Adaptive Biotechnologies (NASDAQ:ADPT) reported third-quarter net income and raised its full-year revenue outlook for its minimal residual disease business, as demand for its clonoSEQ cancer testing service increased in both clinical care and drug development. The company
Directly affected
- ADPT Adaptive Biotechnologies-3.2% 30d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Adaptive Biotechnologies belongs to, so it often moves with news about it.
- AMGN Amgen+13.5% 30d
Amgen is a peer of Adaptive Biotechnologies in biological products, (no diagnostic substances); rivals often move on the same news.
- GILD Gilead Sciences+11.0% 30d
Gilead Sciences is a peer of Adaptive Biotechnologies in biological products, (no diagnostic substances); rivals often move on the same news.
- MRNA Moderna+25.4% 30d
Moderna is a peer of Adaptive Biotechnologies in biological products, (no diagnostic substances); rivals often move on the same news.
- ARGX argenx SE-17.7% 14d
argenx SE is a peer of Adaptive Biotechnologies in biological products, (no diagnostic substances); rivals often move on the same news.
- RVMD Revolution Medicines
Revolution Medicines is a peer of Adaptive Biotechnologies in biological products, (no diagnostic substances); rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| ADPT | +5.35% | -6.36% | base | after close | after close | after close | after close |
| XLV | -2.96% | -2.66% | base | after close | after close | after close | after close |
| AMGN | -3.66% | -2.64% | base | after close | after close | after close | after close |
| GILD | -5.08% | -2.33% | base | after close | after close | after close | after close |
| MRNA | -13.80% | -14.51% | base | after close | after close | after close | after close |
| ARGX | -3.61% | -6.09% | base | after close | after close | after close | after close |
| RVMD | -4.55% | -5.69% | base | after close | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Adaptive Biotechnologies Q3 Earnings Call Highlights Yahoo Finance
Source: Yahoo Finance
This story
| Company | When | Move | Status |
|---|---|---|---|
| ADPT | three days earlier | -6.36% | final price |
| ADPT | five days earlier | +5.35% | final price |
| AMGN | three days earlier | -2.64% | final price |
| AMGN | five days earlier | -3.66% | final price |
| ARGX | three days earlier | -6.09% | final price |
| ARGX | five days earlier | -3.61% | final price |
| GILD | three days earlier | -2.33% | final price |
| GILD | five days earlier | -5.08% | final price |
| MRNA | three days earlier | -14.51% | final price |
| MRNA | five days earlier | -13.80% | final price |
| RVMD | three days earlier | -5.69% | final price |
| RVMD | five days earlier | -4.55% | final price |
| XLV | three days earlier | -2.66% | final price |
| XLV | five days earlier | -2.96% | final price |
Trades by members of Congress and officials in the stocks in this story
- Rep. David J. Taylor bought Amgen (AMGN), worth $1,001 - $15,000 on 22 Sep 2026. That is 44 days before publication. Filed 1 Oct 2026. View the filing.
- Rep. David J. Taylor sold Amgen (AMGN), worth $1,001 - $15,000 on 26 Aug 2026. That is 71 days before publication. Filed 5 Sep 2026. View the filing.
- Sen. Sheldon Whitehouse sold Amgen (AMGN) (held by a spouse), worth $1,001 - $15,000 on 12 Aug 2026. That is 85 days before publication. Filed 2 Sep 2026. View the filing.
- Rep. Rohit Khanna sold Gilead Sciences (GILD) (held by a dependent child), worth $1,001 - $15,000 on 10 Aug 2026. That is 87 days before publication. Filed 4 Sep 2026. View the filing.
- Rep. Maria Elvira Salazar sold Moderna (MRNA), worth $1,001 - $15,000 on 24 Sep 2026. That is 42 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Moderna (MRNA) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 62 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Moderna (MRNA), worth $1,001 - $15,000 on 28 Aug 2026. That is 69 days before publication. Filed 8 Oct 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
How solid “Adaptive Biotechnologies Q3 Earnings Call Highlights” looks
12 out of 100
“Adaptive Biotechnologies Q3 Earnings Call Highlights” scores 12 out of 100. The score uses 1 sources.